The BEAUTIFUL study › SPbU Researchers Portal

Standard

The BEAUTIFUL study : Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - Baseline characteristics of the study population. / BEAUTIFUL Investigators.

In: Cardiology (Switzerland), Vol. 110, No. 4, 01.06.2008, p. 271-282.

Research output: Contribution to journal › Article › peer-review

BibTeX

@article{0f1c8bbd5f9a4c2d878be3f6947b38f4,

title = "The BEAUTIFUL study: Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - Baseline characteristics of the study population",

abstract = "Objectives: Ivabradine is a selective heart rate-lowering agent that acts by inhibiting the pacemaker current If in sinoatrial node cells. Patients with coronary artery disease and left ventricular dysfunction are at high risk of death and cardiac events, and the BEAUTIFUL study was designed to evaluate the effects of ivabradine on outcome in such patients receiving optimal medical therapy. This report describes the study population at baseline. Methods: BEAUTIFUL is an international, multicentre, randomized, double-blind trial to compare ivabradine with placebo in reducing mortality and cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction (ejection fraction <40%). Results: A total of 10,917 patients were randomized. At baseline, their mean age was 65 years, 83% were male, 98% Caucasian, 88% had previous myocardial infarction, 37% had diabetes, and 40% had metabolic syndrome. Mean ejection fraction was 32% and resting heart rate was 71.6 bpm. Concomitant medications included beta-blockers (87%), renin-angiotensin system agents (89%), antithrombotic agents (94%), and lipid-lowering agents (76%). Conclusions: Main results from BEAUTIFUL are expected in 2008, and should show whether ivabradine, on top of optimal medical treatment, reduces mortality and cardiovascular events in this population of high-risk patients.",

keywords = "Coronary artery disease, Heart rate, Ivabradine, Left ventricular dysfunction, Mortality",

author = "{BEAUTIFUL Investigators} and Kim Fox and R. Ferrari and I. Ford and Steg, {P. G.} and M. Tendera and {Cohen Arazi}, H. and Nul, {D. R.} and {Ahuad Guerrero}, {R. A.} and Luciardi, {H. L.} and Sinisi, {V. A.} and Perna, {E. R.} and Schygiel, {P. O.} and Sanjurjo, {M. S.} and Fernandez, {A. A.} and {Del Valle Lobo Marquez}, {L. L.} and Fuselli, {J. J.} and E. Hasbani and Iba{\~n}ez, {J. O.} and Cartasegna, {L. R.} and Lembo, {L. A.} and J. Thierer and S. Varini and Buscema, {J. J.} and Orlandini, {A. D.} and B. Bustos and Guzm{\'a}n, {L. A.} and Luquez, {H. A.} and M. Amuchastegui and Allall, {O. A.} and Iglesias, {R. M.} and Sokn, {F. J.} and Monta{\~n}a, {O. R.} and A. Sanchez and D. Vogel and B. Eber and K. Huber and I. Lang and Pichler and Dendale, {P. A.} and M. Vanderheyden and {van Mieghem}, W. and P. Chenu and A. Friart and L. Missault and Vachiery, {J. L.} and P. Materne and Fran{\c c}ois, {B. A.} and V. Sirakova and Perepech, {N. B.} and O. Karpenko",

note = "Funding Information: We gratefully acknowledge the helpful suggestions of K. Hege and thank him and his colleagues at Steward Observatory for sharing this stellar speckle interferometry data with us. Programming assistance by C. Roussi is also acknowledged. This work was supported by the Air Force Office of Scientific Research under Contract No. F49620-80-C-0006.",

year = "2008",

month = jun,

day = "1",

doi = "10.1159/000112412",

language = "English",

volume = "110",

pages = "271--282",

journal = "Cardiology",

issn = "0008-6312",

publisher = "S. Karger AG",

number = "4",

}

RIS

TY - JOUR

T1 - The BEAUTIFUL study

T2 - Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - Baseline characteristics of the study population

AU - BEAUTIFUL Investigators

AU - Fox, Kim

AU - Ferrari, R.

AU - Ford, I.

AU - Steg, P. G.

AU - Tendera, M.

AU - Cohen Arazi, H.

AU - Nul, D. R.

AU - Ahuad Guerrero, R. A.

AU - Luciardi, H. L.

AU - Sinisi, V. A.

AU - Perna, E. R.

AU - Schygiel, P. O.

AU - Sanjurjo, M. S.

AU - Fernandez, A. A.

AU - Del Valle Lobo Marquez, L. L.

AU - Fuselli, J. J.

AU - Hasbani, E.

AU - Ibañez, J. O.

AU - Cartasegna, L. R.

AU - Lembo, L. A.

AU - Thierer, J.

AU - Varini, S.

AU - Buscema, J. J.

AU - Orlandini, A. D.

AU - Bustos, B.

AU - Guzmán, L. A.

AU - Luquez, H. A.

AU - Amuchastegui, M.

AU - Allall, O. A.

AU - Iglesias, R. M.

AU - Sokn, F. J.

AU - Montaña, O. R.

AU - Sanchez, A.

AU - Vogel, D.

AU - Eber, B.

AU - Huber, K.

AU - Lang, I.

AU - Pichler,

AU - Dendale, P. A.

AU - Vanderheyden, M.

AU - van Mieghem, W.

AU - Chenu, P.

AU - Friart, A.

AU - Missault, L.

AU - Vachiery, J. L.

AU - Materne, P.

AU - François, B. A.

AU - Sirakova, V.

AU - Perepech, N. B.

AU - Karpenko, O.

N1 - Funding Information: We gratefully acknowledge the helpful suggestions of K. Hege and thank him and his colleagues at Steward Observatory for sharing this stellar speckle interferometry data with us. Programming assistance by C. Roussi is also acknowledged. This work was supported by the Air Force Office of Scientific Research under Contract No. F49620-80-C-0006.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Objectives: Ivabradine is a selective heart rate-lowering agent that acts by inhibiting the pacemaker current If in sinoatrial node cells. Patients with coronary artery disease and left ventricular dysfunction are at high risk of death and cardiac events, and the BEAUTIFUL study was designed to evaluate the effects of ivabradine on outcome in such patients receiving optimal medical therapy. This report describes the study population at baseline. Methods: BEAUTIFUL is an international, multicentre, randomized, double-blind trial to compare ivabradine with placebo in reducing mortality and cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction (ejection fraction <40%). Results: A total of 10,917 patients were randomized. At baseline, their mean age was 65 years, 83% were male, 98% Caucasian, 88% had previous myocardial infarction, 37% had diabetes, and 40% had metabolic syndrome. Mean ejection fraction was 32% and resting heart rate was 71.6 bpm. Concomitant medications included beta-blockers (87%), renin-angiotensin system agents (89%), antithrombotic agents (94%), and lipid-lowering agents (76%). Conclusions: Main results from BEAUTIFUL are expected in 2008, and should show whether ivabradine, on top of optimal medical treatment, reduces mortality and cardiovascular events in this population of high-risk patients.

AB - Objectives: Ivabradine is a selective heart rate-lowering agent that acts by inhibiting the pacemaker current If in sinoatrial node cells. Patients with coronary artery disease and left ventricular dysfunction are at high risk of death and cardiac events, and the BEAUTIFUL study was designed to evaluate the effects of ivabradine on outcome in such patients receiving optimal medical therapy. This report describes the study population at baseline. Methods: BEAUTIFUL is an international, multicentre, randomized, double-blind trial to compare ivabradine with placebo in reducing mortality and cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction (ejection fraction <40%). Results: A total of 10,917 patients were randomized. At baseline, their mean age was 65 years, 83% were male, 98% Caucasian, 88% had previous myocardial infarction, 37% had diabetes, and 40% had metabolic syndrome. Mean ejection fraction was 32% and resting heart rate was 71.6 bpm. Concomitant medications included beta-blockers (87%), renin-angiotensin system agents (89%), antithrombotic agents (94%), and lipid-lowering agents (76%). Conclusions: Main results from BEAUTIFUL are expected in 2008, and should show whether ivabradine, on top of optimal medical treatment, reduces mortality and cardiovascular events in this population of high-risk patients.

KW - Coronary artery disease

KW - Heart rate

KW - Ivabradine

KW - Left ventricular dysfunction

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=46349083598&partnerID=8YFLogxK

U2 - 10.1159/000112412

DO - 10.1159/000112412

M3 - Article

C2 - 18595216

AN - SCOPUS:46349083598

VL - 110

SP - 271

EP - 282

JO - Cardiology

JF - Cardiology

SN - 0008-6312

IS - 4

ER -

ID: 88567023

The BEAUTIFUL study: Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - Baseline characteristics of the study population

Standard

Harvard

APA

Vancouver

Author

BibTeX

RIS